A carregar...
Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough
PURPOSE. The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD‐L1) prote...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6263127/ https://ncbi.nlm.nih.gov/pubmed/29703766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0034 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|